Popular Articles
Teeth Whitening

A Novel Communication Role For CYP17A1 In The Progression Of Castration-Resistant Prostate Cancer
UroToday.com - This publication describes our unique finding that the steroidogenic enzyme CYP17A1 is present in prostate derived exosomes, isolated from human serum. We also describe CYP17A1 expression in human prostate tissues during castration resistant progression of cancer and identify a subcellular pattern of distribution for CYP17A1 consistent with a secretory protein in human prostate tissues, similar to that of PSA.
generic viagra online
Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (Mesalamine) Delayed-Release Tablets For Moderately Active Ulcerative Colitis
Procter & Gamble Pharmaceuticals (P&GP) announced the availability of Asacol HD (mesalamine) delayed-release tablets, which are indicated for the treatment of moderately active ulcerative colitis (UC), a form of inflammatory bowel disease. UC involves inflammation of the lining of the colon and rectum and is typically characterized by flares followed by periods of remission. Moderately active UC is characterized by tougher symptoms than mildly active UC. Asacol HD is proven to help treat these tougher flares of moderately active UC. Asacol HD was approved by the U.S. Food and Drug Administration (FDA) based on evaluations from the ASCEND studies [Assessing the Safety and Clinical Efficacy of a New Dose of 5-ASA (4.8 g/day 800 mg tablet)].
News of the day
MADIT-CRT Trial Meets Primary Endpoint
Boston Scientific Corporation (NYSE: BSX) and the University of Rochester Medical Center announced that the landmark MADIT-CRT trial has met its primary endpoint. Preliminary results show Boston Scientific cardiac resynchronization therapy defibrillators (CRT-Ds) to be associated with a significant 29 percent reduction (p=0.003) in death or heart failure interventions when compared to traditional implantable cardioverter defibrillators (ICDs). High risk(1), asymptomatic or mildly symptomatic, New York Heart Association (NYHA) Class I and II(2) patients were enrolled in MADIT-CRT. The MADIT-CRT Executive Committee expects to present and publish the trial"s full results later this year.
Oncology

Stroke Patients Less Likely To Meet Treatment Goals Than Heart Disease Patients

A majority of high-risk stroke patients are less likely to meet clinical treatment targets to prevent repeat stroke or heart attacks compared to those with heart disease, suggesting the need to examine new therapeutic strategies, according to a study led by St. Michael"s Hospital neurologist Dr. Gustavo Saposnik. What"s more, medical procedures or ongoing specialty care may improve patients" awareness and consequent treatment success. The study, an analysis of 4,933 outpatients with a past history of heart attack and cerebrovascular disease (stroke) across Canada, found: * About 30 per cent of patients with heart disease achieved target blood pressure and LDL-cholesterol levels * Only 20 per cent of stroke patients met target blood pressure and LDL-cholesterol levels. (At the time of the study, Canadian guidelines recommended a LDL-cholesterol target of less than 2.5 mmol/L and a blood pressure target of less than 140/90 mm Hg or less than 130/80 mm Hg for diabetic patients). * Among stroke patients, women were also less likely to meet the targets despite a similar medical history of treatment with antihypertensive and LDL-cholesterol-lowering therapies. "With stroke the third leading cause of death in Canada and its prevalence expected to jump exponentially in the next 20 years, more effective therapeutic strategies are necessary to treat patients," said Dr. Saposnik. "By examining clinical management practices, we can better identify the gaps in patient care so that we can improve the health of stroke and heart disease patients." According to the study, inappropriate drug or dose selection, lack of aggressive management, patient nonadherence or limited drug efficacy may pose barriers to poor treatment success. The researchers suggest differences in the emphasis of recommended targets between heart and stroke prevention guidelines may account for the gap. "Despite the effectiveness and benefits of antihypertensive and lipid-lowering therapies, management of heart disease and stroke patients remains poor," said St. Michael Hospital cardiologist Dr. Shaun Goodman, who created the database used in the study. "A significant proportion of patients who failed to meet guidelines within our study were stroke patients and women. Quality improvement strategies should target these patient subgroups so that we can develop benchmarks that can lead to improved clinical practice." The study, which appeared in the Journal of the American Heart Association, was a collaborative effort involving medical professionals from cardiology, endocrinology and neurology at the Hospital led by Dr. Saposnik, Dr. Andrew Tan and Dr. Goodman. Julie Saccone St. Michael"s Hospital


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):